SGLT 2 INHIBITORS | Latest News RSS feed


New FDA Extension for Farxiga and Xigduo XR

Dapagliflozin is an antidiabetic agent that belongs to the class of sodium-glucose cotransporter 2 (SGLT-2) inhibitors. This medication works by enhancing glucose elimination via urine. Dapagliflozin ... read more

Amelioration of diabetic nephropathy by SGLT2 inhibitors independent of its glucose-lowering effect: A possible role of SGLT2 in mesangial cells

Several clinical studies have shown the beneficial effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors on diabetic nephropathy. The underlying mechanisms are not fully understood. We found ... read more

Inpatient diabetic ketoacidosis more frequent with SGLT2 inhibitor use

Adults with type 2 diabetes prescribed an SGLT2 inhibitor were more likely to develop diabetic ketoacidosis during a hospital admission vs. nonusers of the therapy, according to findings from a ... read more

Looking for another news?

SGLT2 inhibitors in Type 1 Diabetes: What Are the Risks?

My name is Simon Heller. I'm professor of clinical diabetes at the University of Sheffield in the north of England and I'm going to discuss the recent approval [EU positive opinion for type 1 diabetes ... read more

Low EF Heart Failure Benefits Most From SGLT2 Diabetes Drug

Clyde Yancy, MD, of Northwestern University in Chicago, noted the consensus recommendation support given to using SGLT2 inhibitors and other drugs proven to have a heart benefit in diabetes. However, ... read more

5 Takeaways From the 2019 American College of Cardiology Meeting

For SGLT2 inhibitors and a fish oil capsule, there was plenty of good news; for aspirin, not so much. A recap of the American College of Cardiology's 68th Annual Scientific Session, held March 16-18, ... read more

Lexicon Falls as FDA Denies Approval to Type I Diabetes Drug

Lexicon is developing the candidate in collaboration with Sanofi SNY. Zynquista is a dual SGLT1 and SGLT2 inhibitor evaluated in combination with insulin for the treatment of type I diabetes in ... read more

SGLT2 Inhibitors Reduce Heart Failure Risk in T2D With Reduced EF

Sodium-glucose cotransporter-2 (SGLT2) inhibitors reduce the risk for heart failure (HF) hospitalization and death in patients with type 2 diabetes (T2D) and with either reduced or preserved ejection ... read more

Lexicon, Sanofi hit with CRL on Zynquista; Recro with IV meloxicam gets one, too

Less favorable was a small incidence of diabetic ketoacidosis (DKA) in the treatment arms, an issue that has dogged SGLT2 inhibitors as a class. And that's where FDA briefing documents related to the ... read more

SGLT-2 inhibitors work by inducing a fasting state that triggers metabolic benefits

SGLT-2 inhibitors are a relatively new class of diabetes drugs that have shown many benefits for people with type 2 diabetes who have not responded well to previous interventions, including diet ... read more

SGLT2 Inhibitors Work by Inducing Fasting State, Joslin Center Scientist Says

The study illuminates how the weight loss, reduction in fatty liver disease, and a decreased risk for cardiovascular disease happens in patients taking SGLT2 inhibitors. Researchers said that they ... read more

FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us